✦ LIBER ✦

Power doppler ultrasonographic monitoring of response to anti–tumor necrosis factor therapy in patients with rheumatoid arthritis

✍ Scribed by Esperanza Naredo; Ingrid Möller; Ana Cruz; Loreto Carmona; Jesüs Garrido

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 219 KB
Volume: 58
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23682

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genotoxicity of anti–tumor necrosis fact

Genotoxicity of anti–tumor necrosis factor therapy in patients with juvenile idiopathic arthritis

✍ Erkan Demirkaya; Ismet Cok; Emre Durmaz; Onur K. Ulutas; Nuray Aktay Ayaz; Nesri 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## Objective To assess the possible effects of both inflammation and the anti–tumor necrosis factor agents (anti‐TNF) on DNA damage with a specific assay, and their effects on the repair capacity of DNA. ## Methods From a group of 20 children with juvenile idiopathic arthritis (JIA),

Rheumatoid arthritis risk allele PTPRC i

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti–tumor necrosis factor α therapy

✍ Jing Cui; Saedis Saevarsdottir; Brian Thomson; Leonid Padyukov; Annette H. M. va 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB 👁 1 views

Modulation of CD28 expression with anti–

Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritis

✍ Ewa Bryl; Abbe N. Vallejo; Eric L. Matteson; Jacek M. Witkowski; Cornelia M. Wey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 1 views

Improvement in patient-reported outcomes

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy

✍ Keystone, E. ;Burmester, G. R. ;Furie, R. ;Loveless, J. E. ;Emery, P. ;Kremer, J 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 373 KB 👁 2 views

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif